MRK posts better-than-expected first-quarter results but trims its 2025 EPS outlook due to anticipated one-time charges.

Selling, general and administrative expenses were $2.6 billion in the first quarter, Merck noted, an increase of 3% compared with the first quarter of 2024. The increase was primarily due to higher ...

In vaccines, sales of HPV vaccines — Gardasil and Gardasil 9 — fell 40% to $1.33 billion ... Sales of the pneumococcal 15-valent conjugate vaccine Vaxneuvance rose 7% to $230 million ...

vaccines Gardasil and Gardasil 9, marking a continued setback for the company’s second-highest selling product. During MSD’s Q1 2025 earnings call on 24 April, chief financial officer Caroline ...

Sales Grew 10% GARDASIL/GARDASIL 9 Sales Declined 41% to $1.3 Billion; Excluding the Impact of Foreign Exchange, Sales Declined 40% GAAP EPS Was $2.01; Non-GAAP EPS Was $2.22 Presented Compelling ...

GARDASIL/GARDASIL 9 sales fell ~41% YoY to $1.3B following a ~17% YoY drop in Q4 2024, mainly due to lower demand in China. Meanwhile, Winrevair, a treatment the company markets with Bristol Myers ...

The drugmaker is still dealing with the fallout over its HPV vaccine Gardasil in China, where a drop in demand forced it to halt shipments and rescind its previous forecast of $11 billion in ...